Compare VIV & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIV | ILMN |
|---|---|---|
| Founded | 1973 | 1998 |
| Country | Brazil | United States |
| Employees | 35010 | 8650 |
| Industry | Telecommunications Equipment | Medical Specialities |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.8B | 21.6B |
| IPO Year | 1998 | 2000 |
| Metric | VIV | ILMN |
|---|---|---|
| Price | $14.08 | $142.22 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 17 |
| Target Price | $14.80 | ★ $124.24 |
| AVG Volume (30 Days) | 1.0M | ★ 1.5M |
| Earning Date | 05-12-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.47% | N/A |
| EPS Growth | N/A | ★ 170.87 |
| EPS | N/A | ★ 0.87 |
| Revenue | N/A | ★ $4,343,000,000.00 |
| Revenue This Year | $9.22 | $6.47 |
| Revenue Next Year | $5.52 | $5.58 |
| P/E Ratio | ★ $22.12 | $164.07 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.73 | $78.80 |
| 52 Week High | $17.26 | $155.53 |
| Indicator | VIV | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 32.99 | 59.96 |
| Support Level | $11.81 | $116.54 |
| Resistance Level | $16.46 | $153.43 |
| Average True Range (ATR) | 0.34 | 6.15 |
| MACD | -0.19 | 0.52 |
| Stochastic Oscillator | 7.71 | 74.21 |
Telefonica Brasil, known as Vivo, is the largest wireless carrier in Brazil with 103 million customers, which is equal to about 38% market share. The firm is strongest in the postpaid business, where it has 72 million customers, or about 40% share of this market. Wireless services and equipment contribute about 70% of total revenue. Vivo is the incumbent fixed-line telephone operator in Sao Paulo state and also owns an extensive fiber network across the country. The firm provides internet access to 8 million households on this network. The firm also sells pay-TV and phone services to its fixed-line customers. Finally, corporate data and IT services, including cloud computing support, contribute about 10% of total revenue.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.